- Home
- AIDX vs ASBP Comparison
AIDX vs ASBP Comparison
Compare AIDX & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIDX | ASBP |
|---|---|---|
| Founded | N/A | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 6.8M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AIDX | ASBP |
|---|---|---|
| Price | $0.62 | $8.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 86.3K | 25.9K |
| Earning Date | N/A | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.48 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,045,133.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.71 | N/A |
| 52 Week Low | $0.40 | $0.05 |
| 52 Week High | $14.09 | $8.80 |
Technical Indicators
Market Signals| Indicator | AIDX | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 61.81 |
| Support Level | $0.52 | $0.16 |
| Resistance Level | $0.70 | N/A |
| Average True Range (ATR) | 0.06 | 0.53 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 86.29 | 71.26 |
Price Performance
Historical ComparisonAbout AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.